rAd-IFNalpha + Syn3

rAd-IFNalpha + Syn3 is a combination gene therapy product consisting of a replication-deficient recombinant adenovirus vector encoding the human interferon alpha-2b (IFNα-2b) gene, formulated with Syn3, a surfactant excipient. The therapy is administered intravesically (directly into the bladder) for the treatment of high-grade, non–muscle-invasive bladder cancer (NMIBC), especially in patients refractory to or relapsed after Bacillus Calmette-Guerin (BCG) treatment[1][2][3][7]. Syn3 enhances adenoviral gene transfer by disrupting the bladder glycocalyx and facilitating viral vector binding and transfection of both normal and cancerous urothelial cells[3]. The adenovirus vector delivers the IFNα-2b gene, leading to sustained local production and secretion of interferon alpha, which exerts antitumor effects via multiple mechanisms including induction of apoptosis (via endoplasmic reticulum stress and caspase activation), recruitment and activation of T cells, and inhibition of angiogenesis[3][7]. The therapy demonstrated a favorable safety profile and promising efficacy in clinical trials, with manageable side effects and meaningful rates of recurrence-free survival[1][2][3][6][7].

Brand names

Instiladrin

Other names

nadofaragene firadenovec + Syn3recombinant adenovirus IFNalpha + Syn3